<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36096146</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study.</ArticleTitle><Pagination><StartPage>67</StartPage><EndPage>73</EndPage><MedlinePgn>67-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(22)00527-8</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(22)00527-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">The BNT162b2 (Pfizer-BioNTech) two-dose vaccine regiment for children and the BNT162b2 third dose for adolescents were approved shortly before the SARS-CoV-2 omicron (B.1.1.529) outbreak in Israel. We aimed to estimate the effects of these vaccines on the rates of confirmed infection against the omicron variant in children and adolescents.</AbstractText><AbstractText Label="METHODS">In this observational cohort study, we extracted data for the omicron-dominated (sublineage BA.1) period. We compared rates of confirmed SARS-CoV-2 infection between children aged 5-10 years 14-35 days after receiving the second vaccine dose with an internal control group of children 3-7 days after receiving the first dose (when the vaccine is not yet effective). Similarly, we compared confirmed infection rates in adolescents aged 12-15 years 14-60 days after receiving a booster dose with an internal control group of adolescents 3-7 days after receiving the booster dose. We used Poisson regression, adjusting for age, sex, socioeconomic status, calendar week, and exposure.</AbstractText><AbstractText Label="FINDINGS">Between Dec 26, 2021, and Jan 8, 2022, we included 1&#x2008;158&#x2008;289 participants. In children aged 5-10 years, the adjusted rate of confirmed infection was 2&#xb7;3 times (95% CI 2&#xb7;0-2&#xb7;5) lower in children who received a second dose than in the internal control group. The adjusted infection rate in children who received a second dose was 102 infections per 100&#x2008;000 risk-days (94-110) compared with 231 infections per 100&#x2008;000 risk-days (215-248) in the corresponding internal control cohort. In adolescents aged 12-15 years, the booster dose decreased confirmed infection rates by 3&#xb7;3 times (2&#xb7;8-4&#xb7;0) compared with in the internal control group. The adjusted infection rate of the booster cohort was 70 per 100&#x2008;000 risk-days (60-81) compared with 232 per 100&#x2008;000 risk-days (212-254) in the internal control cohort.</AbstractText><AbstractText Label="INTERPRETATION">A recent two-dose vaccination regimen with BNT162b2 and a recent booster dose in adolescents substantially reduced the rate of confirmed infection compared with the internal control groups. Future studies are needed to assess the duration of this protection and protection against other outcomes such as paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 and long-COVID.</AbstractText><AbstractText Label="FUNDING">None.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amir</LastName><ForeName>Ofra</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Industrial Engineering and Management, Technion-Israel Institute of Technology, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Yair</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Industrial Engineering and Management, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: yairgo@technion.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandel</LastName><ForeName>Micha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Statistics and Data Science, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bar-On</LastName><ForeName>Yinon M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodenheimer</LastName><ForeName>Omri</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Israel Ministry of Health, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freedman</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ariel University, Ariel, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ash</LastName><ForeName>Nachman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Israel Ministry of Health, Jerusalem, Israel; Ariel University, Ariel, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alroy-Preis</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Israel Ministry of Health, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huppert</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Bio-statistical and Bio-mathematical Unit, The Gertner Institute for Epidemiology &amp; Health Policy Research, Sheba Medical Center, Ramat Gan, Israel; Faculty of Medicine, Tel Aviv University, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milo</LastName><ForeName>Ron</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Infect Dis. 2023 Jan;23(1):5-6. doi: 10.1016/S1473-3099(22)00575-8</RefSource><PMID Version="1">36096145</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>12</Day><Hour>19</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36096146</ArticleId><ArticleId IdType="pmc">PMC9462831</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(22)00527-8</ArticleId><ArticleId IdType="pii">S1473-3099(22)00527-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med. 2022;386:494&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757569</ArticleId><ArticleId IdType="pubmed">34965358</ArticleId></ArticleIdList></Reference><Reference><Citation>Our World in Data  SARS-CoV-2 variants in analyzed sequences. https://ourworldindata.org/grapher/covid-variants-area</Citation></Reference><Reference><Citation>Dorabawila V, Hoefer D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Effectiveness of the BNT162b2 vaccine among children 5&#x2013;11 and 12&#x2013;17 years in New York after the emergence of the omicron variant. medRxiv. 2022 doi: 10.1101/2022.02.25.22271454. published online Feb 28. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.25.22271454</ArticleId><ArticleId IdType="pmc">PMC9107062</ArticleId><ArticleId IdType="pubmed">35559959</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming-Dutra KE, Britton A, Shang N, et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance. JAMA. 2022;327:2210&#x2013;2219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9107063</ArticleId><ArticleId IdType="pubmed">35560036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (delta) variant predominance&#x2014;eight US locations, December 2020&#x2013;August 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1167&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389394</ArticleId><ArticleId IdType="pubmed">34437521</ArticleId></ArticleIdList></Reference><Reference><Citation>Amir O, Goldberg Y, Mandel M, et al. Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine. Nat Commun. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9008037</ArticleId><ArticleId IdType="pubmed">35418201</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics after a national immunization program in Israel. Nat Med. 2021;27:1055&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">33875890</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhsen K, Na'aminh W, Lapidot Y, et al. A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020-February 2021. Lancet Reg Health Eur. 2021;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8177966</ArticleId><ArticleId IdType="pubmed">34109321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn R, Schrag SJ, Verani JR, Lipsitch M. Identifying and alleviating bias due to differential depletion of susceptible people in post-marketing evaluations of COVID-19 Vaccines. Am J Epidemiol. 2022;191:800&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8807238</ArticleId><ArticleId IdType="pubmed">35081612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385:1393&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461568</ArticleId><ArticleId IdType="pubmed">34525275</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On YM, Goldberg Y, Mandel M, et al. Protection against COVID-19 by BNT162b2 booster across age groups. N Engl J Med. 2021;385:2421&#x2013;2430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728796</ArticleId><ArticleId IdType="pubmed">34879188</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a Nationwide mass vaccination setting. N Engl J Med. 2021;384:1412&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Remschmidt C, Wichmann O, Harder T. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review. BMC Infect Dis. 2015;15:429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609091</ArticleId><ArticleId IdType="pubmed">26474974</ArticleId></ArticleIdList></Reference><Reference><Citation>Royal College of Paediatrics and Child Health  Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS)&#x2014;guidance for clinicians. https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims-guidance</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>